SCIENTURE HOLDINGS, INC. Stock-Based Compensation
SCIENTURE HOLDINGS, INC. (SCNX) reported Stock-Based Compensation of $205.78 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-13
- SCIENTURE HOLDINGS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $103.46K, a 36.31% decline year-over-year.
- SCIENTURE HOLDINGS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $102.32K, a 23314.19% increase year-over-year.
- SCIENTURE HOLDINGS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $248.46K, a 56755.61% increase year-over-year.
- SCIENTURE HOLDINGS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $1.66M.
- SCIENTURE HOLDINGS, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $2.07M, a 7986.66% increase from fiscal 2024.
- SCIENTURE HOLDINGS, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $25.58K, a 13.97% decline from fiscal 2023.
- SCIENTURE HOLDINGS, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $29.74K, a 62.43% decline from fiscal 2022.
- SCIENTURE HOLDINGS, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $79.16K, a 23.37% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 9 month as first filed | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $103.46K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $205.78K 10-Q · filed 2026-08-13 | $454.24K derived: sum of 3 quarters · filed 2026-08-13 | $2.11M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2026-03-31 | $102.32K 10-Q · filed 2026-05-15 | $350.78K derived: sum of 2 quarters · filed 2026-05-15 | $2.01M derived: sum of 3 quarters · filed 2026-05-15 | $2.17M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-12-31 | $248.46K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $1.91M derived: sum of 2 quarters · filed 2026-03-30 | $2.07M derived: sum of 3 quarters · filed 2026-08-13 | $2.07M 10-K · filed 2026-03-30 | ||
| 2025-09-30 | $1.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.82M derived: sum of 2 quarters · filed 2026-08-13 | $1.82M 10-Q · filed 2025-11-12 | $1.82M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-09-17 | $1.51M 10-Q · filed 2026-08-13 | |||||
| 2025-06-30 | $162.44K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $162.87K 10-Q · filed 2026-08-13 | $163.31K derived: sum of 3 quarters · filed 2026-08-13 | |||
| 2025-03-31 | $437.00 10-Q · filed 2026-05-15 | $874.00 derived: sum of 2 quarters · filed 2026-05-15 | ||||
| 2024-12-31 | $437.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $25.58K 10-K · filed 2026-03-30 | ||||
| 2024-09-30 | $25.15K 10-Q · filed 2025-11-12 | |||||
| 2024-03-31 | $24.27K 10-Q · filed 2024-06-26 | $28.03K derived: sum of 2 quarters · filed 2024-06-26 | $31.79K derived: sum of 3 quarters · filed 2024-06-26 | $39.57K derived: sum of 4 quarters · filed 2024-06-26 | ||
| 2023-12-31 | $3.76K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-22 | $7.52K derived: sum of 2 quarters · filed 2024-04-22 | $15.30K derived: sum of 3 quarters · filed 2024-04-22 | $29.74K 10-K · filed 2024-04-22 | ||
| 2023-09-30 | $3.76K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-01-16 | $11.54K derived: sum of 2 quarters · filed 2024-01-16 | $25.98K 10-Q · filed 2024-01-16 | $37.70K derived: sum of 4 quarters · filed 2024-06-26 | ||
| 2023-06-30 | $7.78K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-18 | $22.22K 10-Q · filed 2023-08-18 | $33.94K derived: sum of 3 quarters · filed 2024-06-26 | $49.51K derived: sum of 4 quarters · filed 2024-06-26 | ||
| 2023-03-31 | $14.43K 10-Q · filed 2024-06-26 | $26.16K derived: sum of 2 quarters · filed 2024-06-26 | $41.72K derived: sum of 3 quarters · filed 2024-06-26 | $60.81K derived: sum of 4 quarters · filed 2024-06-26 | ||
| 2022-12-31 | $11.72K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-22 | $27.29K derived: sum of 2 quarters · filed 2024-04-22 | $46.38K derived: sum of 3 quarters · filed 2024-04-22 | $79.16K 10-K · filed 2024-04-22 | ||
| 2022-09-30 | $15.56K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-01-16 | $34.66K derived: sum of 2 quarters · filed 2024-01-16 | $67.44K 10-Q · filed 2024-01-16 | -$5.52K derived: sum of 4 quarters · filed 2024-01-16 | ||
| 2022-06-30 | $19.09K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-18 | $51.88K 10-Q · filed 2023-08-18 | -$21.09K derived: sum of 3 quarters · filed 2023-08-18 | -$21.09K derived: sum of 4 quarters · filed 2023-08-18 | ||
| 2022-03-31 | $32.78K 10-Q · filed 2023-05-15 | -$40.18K derived: sum of 2 quarters · filed 2023-05-15 | -$40.18K derived: sum of 3 quarters · filed 2023-05-15 | $21.21K derived: sum of 4 quarters · filed 2023-05-15 | ||
| 2021-12-31 | -$72.96K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | -$72.96K derived: sum of 2 quarters · filed 2022-11-07 | -$11.57K derived: sum of 3 quarters · filed 2022-11-07 | $64.17K 10-K · filed 2022-03-28 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $61.39K derived: sum of 2 quarters · filed 2022-11-07 | $137.13K 10-Q · filed 2022-11-07 | $36.67K 10-Q · filed 2021-10-25 | $212.63K derived: sum of 4 quarters · filed 2022-11-07 | |
| 2021-06-30 | $61.39K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-25 | $137.13K 10-Q · filed 2022-07-25 | $212.63K derived: sum of 3 quarters · filed 2022-07-25 | $339.63K derived: sum of 4 quarters · filed 2022-07-25 | ||
| 2021-03-31 | $75.74K 10-Q · filed 2021-04-26 | $151.24K derived: sum of 2 quarters · filed 2021-04-26 | $278.24K derived: sum of 3 quarters · filed 2021-04-26 | $462.14K derived: sum of 4 quarters · filed 2021-04-26 | ||
| 2020-12-31 | $75.50K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $202.50K derived: sum of 2 quarters · filed 2021-03-29 | $386.41K derived: sum of 3 quarters · filed 2021-03-29 | $448.40K 10-K · filed 2021-03-29 | ||
| 2020-09-30 | $127.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-26 | $310.90K derived: sum of 2 quarters · filed 2020-10-26 | $372.90K 10-Q · filed 2020-10-26 | $407.68K derived: sum of 4 quarters · filed 2021-04-26 | ||
| 2020-06-30 | $183.91K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-27 | $245.90K 10-Q · filed 2020-07-27 | $280.69K derived: sum of 3 quarters · filed 2021-04-26 | $322.29K derived: sum of 4 quarters · filed 2021-04-26 | ||
| 2020-03-31 | $62.00K 10-Q · filed 2021-04-26 | $96.78K derived: sum of 2 quarters · filed 2021-04-26 | $138.38K derived: sum of 3 quarters · filed 2021-04-26 | |||
| 2019-12-31 | $34.78K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $76.39K derived: sum of 2 quarters · filed 2021-03-29 | $176.38K 10-K · filed 2021-03-29 | |||
| 2019-09-30 | $41.60K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-26 | $141.59K 10-Q · filed 2020-10-26 | ||||
| 2019-06-30 | $99.99K 10-Q · filed 2020-07-27 | |||||
| 2015-12-31 | $0.00 10-K · filed 2016-03-28 | |||||
| 2015-06-30 | $0.00 10-Q · filed 2015-07-30 | |||||
| 2014-12-31 | $576.42K 10-K · filed 2016-03-28 | |||||
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-30 | $576.42K 10-Q · filed 2015-07-30 | ||||
| 2014-03-31 | $576.42K 10-Q · filed 2015-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |